Oxyphenisatin acetate exerts antiproliferative activity in breast cancer cells via activating the PERK/eIF2α and AMPK/mTOR signaling pathways, while it has been reported that orlistat inhibits endometrial cancer cell proliferation via attenuating fatty acid metabolism, activating the AMPK/mTOR signaling pathway and inducing cellular stress mediated by the increased PERK expression [13, 23, 24]. The gene discussed is MTOR; the disease is breast cancer.